Company intelligence / Profile preview

Armas Pharmaceuticals Inc.

Freehold, New Jersey, United Statesarmaspharmaceuticals.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Armas Pharmaceuticals has a portfolio of commercial products including generic injectables and oral medications. Their most recent launch was the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market in March 2025[5].

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Small moleculesinjectablesoral solids
Industry: Biotech

Drug pipeline

6 assets

erlotinib

Commercial

Indications: Oncology

5 more assets in the full pipeline.

Request access →

Partnerships

SteriscienceMicro Labs

Beyond the preview

Go deeper on Armas Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armas Pharmaceuticals Inc..

Explore the full profile